Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2020 | 2 |
2021 | 5 |
2022 | 2 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
Page 1
Primary Sjögren's syndrome: new beginning for evidence-based trials.
Lancet. 2022 Jan 8;399(10320):121-122. doi: 10.1016/S0140-6736(21)02644-1. Epub 2021 Nov 30.
Lancet. 2022.
PMID: 34861169
No abstract available.
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
Bowman SJ, Fox R, Dörner T, Mariette X, Papas A, Grader-Beck T, Fisher BA, Barcelos F, De Vita S, Schulze-Koops H, Moots RJ, Junge G, Woznicki JN, Sopala MA, Luo WL, Hueber W.
Bowman SJ, et al.
Lancet. 2022 Jan 8;399(10320):161-171. doi: 10.1016/S0140-6736(21)02251-0. Epub 2021 Nov 30.
Lancet. 2022.
PMID: 34861168
Clinical Trial.
Item in Clipboard
Current and future status of JAK inhibitors.
McLornan DP, Pope JE, Gotlib J, Harrison CN.
McLornan DP, et al.
Lancet. 2021 Aug 28;398(10302):803-816. doi: 10.1016/S0140-6736(21)00438-4.
Lancet. 2021.
PMID: 34454676
Review.
Item in Clipboard
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
Humby F, Durez P, Buch MH, Lewis MJ, Rizvi H, Rivellese F, Nerviani A, Giorli G, Mahto A, Montecucco C, Lauwerys B, Ng N, Ho P, Bombardieri M, Romão VC, Verschueren P, Kelly S, Sainaghi PP, Gendi N, Dasgupta B, Cauli A, Reynolds P, Cañete JD, Moots R, Taylor PC, Edwards CJ, Isaacs J, Sasieni P, Choy E, Pitzalis C; R4RA collaborative group.
Humby F, et al.
Lancet. 2021 Jan 23;397(10271):305-317. doi: 10.1016/S0140-6736(20)32341-2.
Lancet. 2021.
PMID: 33485455
Free PMC article.
Clinical Trial.
Item in Clipboard
Precision medicine in rheumatology: are we getting closer?
Poddubnyy D.
Poddubnyy D.
Lancet. 2021 Jan 23;397(10271):258-259. doi: 10.1016/S0140-6736(20)32652-0.
Lancet. 2021.
PMID: 33485433
No abstract available.
Item in Clipboard
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
Burmester GR, Buttgereit F, Bernasconi C, Álvaro-Gracia JM, Castro N, Dougados M, Gabay C, van Laar JM, Nebesky JM, Pethoe-Schramm A, Salvarani C, Donath MY, John MR; SEMIRA collaborators.
Burmester GR, et al.
Lancet. 2020 Jul 25;396(10246):267-276. doi: 10.1016/S0140-6736(20)30636-X.
Lancet. 2020.
PMID: 32711802
Clinical Trial.
Item in Clipboard
Tapering glucocorticoids in rheumatoid arthritis.
Volkmann ER.
Volkmann ER.
Lancet. 2020 Jul 25;396(10246):218-219. doi: 10.1016/S0140-6736(20)30761-3.
Lancet. 2020.
PMID: 32711782
Free PMC article.
No abstract available.
Item in Clipboard
Cite
Cite